Detalhe da pesquisa
1.
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 386(19): 1793-1803, 2022 05 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35544387
2.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36660819
3.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130809
4.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33308425
5.
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
N Engl J Med
; 379(7): 645-654, 2018 08 16.
Artigo
Inglês
| MEDLINE | ID: mdl-30110589
6.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-28750935
7.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23830355
8.
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
J Infect Dis
; 207(5): 740-8, 2013 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23225901
9.
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS
; 36(2): 195-203, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34652287
10.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34648734
11.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infect Dis
; 8(9): ofab439, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34557563
12.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
N Engl J Med
; 357(23): 2359-70, 2007 Dec 06.
Artigo
Inglês
| MEDLINE | ID: mdl-18057338
13.
Intraspecific variation in thermal acclimation and tolerance between populations of the winter ant, Prenolepis imparis.
Ecol Evol
; 10(11): 4749-4761, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32551058
14.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
15.
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
HIV Clin Trials
; 9(3): 152-63, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-18547902
16.
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
PLoS One
; 13(1): e0190487, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29304154
17.
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
AIDS
; 20(3): 397-404, 2006 Feb 14.
Artigo
Inglês
| MEDLINE | ID: mdl-16439873
18.
Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
HIV Clin Trials
; 11(3): 170-3, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20736153
19.
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Antivir Ther
; 20(3): 343-8, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25321146
20.
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Antivir Ther
; 8(4): 279-87, 2003 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-14518696